Compare Globus Medical Inc. Class A Common Stock (GMED) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Match Group Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Match Group Inc trades at $42.39 (market cap $9.72B). The key difference: Globus Medical Inc. Class A Common Stock and Match Group Inc are close in size by market cap, and Match Group Inc pays a 1.89% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Match Group Inc for 115 Days on average.
| GMED | MTCH | |
|---|---|---|
Market Cap | $10.25B | $9.72B |
Volume | 1,108,124 | 4,140,020 |
Sector | Health | Media |
52-Week High | $96.82 | $44.40 |
52-Week Low | $58.33 | $28.90 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $9.76B | $12.69B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MTCH trades at $42.40, up 2.12% today, with a bullish technical signal and strong support at $41. The company reported a net income margin of 20.17% for 2025, with Q2 2026 EPS beating expectations. Operating cash flow reached $1.08B in 2025, and a $0.20 dividend is scheduled for October 2026. Recent news highlights product innovation at Tinder and growth at Hinge.
The outlook is positive with a consensus price target of $42.29, though high debt levels and competitive pressures pose risks. Analyst sentiment is bullish with 53% buy ratings. Revenue stability and margin expansion support upside potential, but investors should monitor execution on Tinder's turnaround and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
